MaxCyte Deal History & Licensing Activity
MaxCyte is a life sciences. Over the past three years, MaxCyte has been involved in 3 licensing and acquisition transactions, with a primary focus on Cell Therapy (4 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Cell Therapy
Focus Area
Other
MaxCyte Recent Deal Activity
Licensing, acquisition, and partnership transactions involving MaxCyte in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| ExPERT GTx | Genentech | Cell Therapy | Unknown | license | Jul 21, 2026 |
MaxCyte Pipeline Focus
Therapeutic areas and modalities where MaxCyte is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches MaxCyte's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Other assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Cell Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for cell therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About MaxCyte Licensing & Deal Activity
MaxCyte is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, MaxCyte ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for MaxCyte include Other (3 deals and trials), and Oncology (1 deal and trial). In terms of modality, MaxCyte has shown particular interest in cell therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for MaxCyte and 700+ other biopharma companies. Use our Solidus to benchmark your asset against MaxCyte's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.